At a time when the industry is struggling with innovation, it might do well to learn a lesson from a few great innovators.
Nov 1, 2011
By:
Michelle Hoffman
At a time when the industry is struggling with innovation, it might do well to learn a lesson from a few great innovators.
|
A report commissioned by FDA evaluates the QbD paradigm.
Sep 1, 2011
By:
Michelle Hoffman
A report commissioned by FDA evaluates the QbD paradigm.
|
Are biosimilars the next big thing or just the next big bubble?
Aug 1, 2011
By:
Michelle Hoffman
Are biosimilars the next big thing or just the next big bubble?
|
Which route will we take to arrive at a national stem-cell policy?
Jul 1, 2011
By:
Michelle Hoffman
Which route will we take to arrive at a national stem-cell policy?
|
Those who doubt there's faith in science, should check out our annual Bioprocessing Survey.
May 1, 2011
By:
Michelle Hoffman
Those who doubt there's faith in science, should check out our annual Bioprocessing Survey.
|
Research and development headed for divorce.
Apr 1, 2011
By:
Michelle Hoffman
Research and development headed for divorce.
|
Capable of great works, pharma too often yields to the lesser angels of its nature
Feb 1, 2011
By:
Michelle Hoffman
Capable of great works, pharma too often yields to the lesser angels of its nature
|
So often a leader on the world stage, the US is a laggard when it comes to regulating follow-on biologics.
Jan 1, 2011
By:
Michelle Hoffman
So often a leader on the world stage, the US is a laggard when it comes to regulating follow-on biologics.
|
|
